The Evolution of the Patient Experience

Posted by Ian Wilcox on Wed, Aug 28, 2019

With the healthcare business model constantly evolving, and new technologies continuously being adopted, the pharmaceutical landscape and the role of healthcare providers is sure to look radically different a few decades down the line.

I recently spoke with Dr. Roland Turck, managing partner of international biotech consulting firm TurckBio, about some of the biggest trends impacting pharma today, from AI to scientific advancements to bridging the divide between medical and commercial. Here are his thoughts on how the industry will evolve for patients and providers. 


>
Read More

How to Survive in Pharma's Payer-Empowered World

Posted by Ed Schoonveld on Fri, Feb 15, 2019

This blog post was originally published on ZS's pricing and access blog, The Price of Global Health.

Until recently, commercial success for a prescription drug mainly involved getting the drug on payer formulary and creating pull-through with sales force efforts toward physicians. Success was defined as securing full, unrestricted access and building significant share through share of voice. The rapidly rising cost of healthcare, new emerging pharmaceutical technologies with breakthrough potential, public concerns over drug pricing, and a gradual shift from fee-for-service to value-based payment models are transforming the pharmaceutical market. Today’s market is much more complicated, as public and private payer management is more restrictive, medical communities are more willing to engage in value vs. cost trade-offs, and providers are taking a more holistic and integrated healthcare delivery focus.


>
Read More

First Launch Commercialization Strategy: Go It Alone or Partner?

Posted by Renuka Agarwal on Fri, Feb 01, 2019

Ben Hohn, Cody Powers and Judith Kulich co-wrote this article with Renuka Agarwal.

The 2019 JPMorgan Chase Healthcare Conference kicked off with a bang as Eli Lilly announced its acquisition of Loxo Oncology for $8 billion. Loxo, a young biotechnology company that partnered with Bayer to launch its first asset, Vitrakvi, in 2018, isn’t a unique story: In today’s environment, the number of first launches for U.S.-based companies—defined by ZS as the first marketed assets of companies that have FDA “novel” status—is rapidly increasing. There were only three first launches from U.S.-based companies in 2011 compared to an astounding 16 first launches in 2018, primarily in oncology, according to ZS research.


>
Read More

Three Things That Pharma Executives Must Do to Keep Pace With the Healthcare Evolution

Posted by Ian Wilcox on Thu, Dec 20, 2018

Just over a week ago, CVS Health announced that it had closed the deal on the merger heard ’round the world: the highly anticipated acquisition of insurance giant Aetna. CVS Health President and Chief Executive Officer Larry Merlo said in a statement that the merger will “transform the consumer health experience and build healthier communities through a new, innovative healthcare model that is local, easier to use, less expensive and puts consumers at the center of their care.”


>
Read More

Making the Case for a New Analytics Consumption Model

Posted by ZS Editors on Thu, Nov 29, 2018

Industries like retail and technology are transitioning to an AI-driven, personalized approach to surfacing insights to end users, and they’re reaping the benefits. Life sciences companies have the same opportunity to capitalize on the runaway growth in data and rethink the way that analytics are consumed.  

ZS recently partnered with IDC to study how commercial life sciences teams are currently consuming data, and to determine their data and analytics pain points. The study revealed that sales and marketing professionals in life sciences want


>
Read More